Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study

QR Code

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study

Background. Interleukin (IL) 6 plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors (i) used to treat RA patients may have an antidepressant effect.Objective – to evaluate the effectiveness of Russian iIL-6 olokizumab (OKZ) in reducing sym...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. A. Lisitsyna, A. A. Abramkin, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, A. B. Borisova, V. G. Ignatiev, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2023-04-01
Series:	Научно-практическая ревматология
Subjects:	interleukin-6 rheumatoid arthritis depression cognitive disorders olokizumab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3321
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
by: G. A. Togizbayev, et al.
Published: (2025-06-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
by: N. A. Lapkina, et al.
Published: (2023-08-01)

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
by: I. M. Patrikeeva, et al.
Published: (2025-02-01)

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience
by: A. M. Lila, et al.
Published: (2024-06-01)

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
by: E. S. Kuvardin, et al.
Published: (2022-11-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
by: P. A. Shesternya, et al.
Published: (2025-04-01)

The effect of olokizumab on rheumatoid arthritis patient’s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1)
by: E. L. Nasonov, et al.
Published: (2021-03-01)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
by: A. A. Baranov, et al.
Published: (2023-06-01)

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. A. Akimova, et al.
Published: (2023-03-01)

Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. V. Fedorova, et al.
Published: (2024-06-01)

Cognitive impairments in patients with rheumatoid arthritis and comorbid anxiety and depressive disorders: Outcomes of the five-years prospective study
by: A. A. Abramkin, et al.
Published: (2024-11-01)

Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes
by: N. A. Lapkina, et al.
Published: (2023-10-01)

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
by: E. V. Tavlueva, et al.
Published: (2022-12-01)

Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis
by: L. V. Kondratyeva, et al.
Published: (2025-07-01)

Proinflammatory cytokines and depression in rheumatoid arthritis
by: Tatyana Andreyevna Lisitsyna, et al.
Published: (2013-06-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders
by: T. A. Lisitsyna, et al.
Published: (2019-07-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2017-09-01)

Efficacy of olocizumab in treatment of COVID-19 patients
by: T. V. Goma, et al.
Published: (2022-12-01)

IL-31 and IL-33 in rheumatoid arthritis patients
by: N. A. Lapkina, et al.
Published: (2022-11-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

IMPACT OF COMORBID MENTAL DISORDERS ON THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin
Published: (2016-07-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Rheumatoid arthritis and bacterial infections
by: N L Prokopjeva, et al.
Published: (2008-02-01)

Antidepressants administration in rheumatoid arthritiswith comorbid depression
by: N V Yaltseva, et al.
Published: (2009-02-01)

Association of TNF-α and IL-6 Concentrations with Depression in Patients with Rheumatoid Arthritis
by: Jelena Mrđa, et al.
Published: (2025-06-01)

Depressive disturbances in patients with rheumatoid arthritis
by: Y S Fofanova, et al.
Published: (2009-08-01)

SOME BONE METABOLIC PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
by: Svetlana Mikhailovna Antonova, et al.
Published: (2010-08-01)

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients
by: V. I. Petrov, et al.
Published: (2025-03-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
by: E. L. Nasonov, et al.
Published: (2018-01-01)

Psychological characteristics of patients with rheumatoid arthritis with severe anxiety and depression
by: I. N. Abrosimov, et al.
Published: (2025-02-01)

Efficacy and safety of levilimab in the treatment of rheumatoid arthritis in real-life clinical practice: first results of the HELIOS observational study
by: A. M. Lila, et al.
Published: (2024-06-01)

The profile of comorbid conditions and the structure of mortality in patients with rheumatoid arthritis in the Stavropol Territory: preliminary results
by: I. N. Shchendrigin, et al.
Published: (2022-09-01)

The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors?
by: E. L. Nasonov, et al.
Published: (2023-04-01)

High efficacy and retention rate of levilimab in the treatment of patients with rheumatoid arthritis in real-life practice
by: A. I. Zagrebneva, et al.
Published: (2025-03-01)

Role of interleukin-6 in the development of atherosclerosis in rheumatoid arthritis
by: Elena Vasilyevna Udachkina, et al.
Published: (2013-10-01)